Item 1.01 Entry into a Material Definitive Agreement.
On February 22, 2023, the Company and U.S. Bank Trust Company, National
Association (as successor to U.S. Bank National Association) (the "Convertible
Notes Trustee"), entered into a First Supplemental Indenture (the "Supplemental
Indenture"), dated as of February 22, 2023, which supplements the Indenture,
dated as of May 29, 2020 (as supplemented by the Supplemental Indenture, the
"Indenture"), by and between the Company and the Convertible Notes Trustee,
governing the Company's 3.00% Senior Convertible Notes due 2025 (the
"Convertible Notes"), of which approximately $316.3 million aggregate principal
amount was outstanding on February 21, 2023.
The Supplemental Indenture provides that, from and after the Effective Time, the
right to convert each $1,000 principal amount of the Convertible Notes changed
into a right to convert such principal amount of the Convertible Notes into
$18.00 in cash multiplied by the Conversion Rate (as defined in the Indenture),
which shall be fixed until the Maturity Date (as defined in the Indenture) at
22.5052 shares of Company Common Stock per $1,000 principal amount of
Convertible Notes. Accordingly, subject to and upon compliance with the
provisions of the Indenture, for all conversions for which the relevant
Conversion Date (as defined in the Indenture) occurs from and after the
Effective Time, the consideration due upon conversion of each $1,000 principal
amount of Convertible Notes will be solely cash in an amount equal to $405.0936
per $1,000 principal amount of Notes.
The foregoing description of the Supplemental Indenture does not purport to be
complete and is subject to, and qualified in its entirety by, the full text of
the Supplemental Indenture, which is included as Exhibit 4.1 hereto and
incorporated into this Item 1.01 by reference.
Item 1.02 Termination of a Material Definitive Agreement.
On February 22, 2023, the Company terminated the Interim Loan and Guaranty
Agreement, dated as of November 14, 2022 (the "Interim Loan and Guaranty
Agreement"), by and between Amazon.com Services LLC and the Company. Upon such
termination, all rights, obligations or liabilities under the Interim Loan and
Guaranty Agreement were fully and unconditionally released and discharged.
Item 2.01 Completion of Acquisition or Disposition of Assets.
As described in the Introductory Note, on February 22, 2023, the Merger was
completed. Upon the consummation of the Merger, the Company became an indirect
wholly owned subsidiary of Parent. The disclosure under the Introductory Note is
incorporated herein by reference.
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial
Obligation or an Obligation under an Off-Balance Sheet Arrangement.
The description contained under the Introductory Note above and in Item 1.01 of
this Current Report on Form 8-K is hereby incorporated by reference in its
entirety into this Item 2.04.
The consummation of the Merger constitutes a Fundamental Change and a Share
Exchange Event (each, as defined in the Indenture) under the Indenture. The
effective date of such Fundamental Change and Share Exchange Event is
February 22, 2023, the date of the consummation of the Merger. Accordingly,
following the Merger, each holder of the Convertible Notes has the right to
(i) convert each $1,000 principal amount of Convertible Notes into $405.0936 in
cash prior to 5:00 p.m., New York City time, on March 22, 2023, or (ii) require
that the Company repurchase such holder's Convertible Notes for cash at a
repurchase price equal to the principal amount of such Convertible Notes, plus
accrued and unpaid interest thereon to, but excluding, the repurchase date of
March 23, 2023 (the "Fundamental Change Repurchase Right"). To exercise the
Fundamental Change Repurchase Right, a holder must (i) deliver a notice in
compliance with The Depository Trust Company's ("DTC") procedures exercising
such holder's Fundamental Change Repurchase Right and (ii) validly deliver such
holder's Convertible Notes through DTC's transmittal procedures, in each case,
prior to 5:00 p.m., New York City time, on March 22, 2023. The Company will
repurchase the Convertible Notes pursuant to the Fundamental Change Repurchase
Right in accordance with the terms and conditions of an offer to purchase, dated
February 22, 2023, issued to the holders of the Convertible Notes, and this
Current Report on Form 8-K does not constitute an offer to repurchase the
Convertible Notes.
--------------------------------------------------------------------------------
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
The disclosures under the Introductory Note are incorporated herein by
reference. On February 21, 2023, the Company notified The Nasdaq Global Select
Market ("Nasdaq") of the pending consummation of the Merger. On February 22,
2023, the Company requested that Nasdaq (A) suspend trading of the Shares
effective before the opening of trading on February 22, 2023 and (B) file with
the SEC a Form 25 Notification of Removal from Listing and/or Registration under
Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), to effect the delisting of the Shares from Nasdaq and to deregister the
Shares under Section 12(b) of the Exchange Act. In addition, the Company intends
to file with the SEC a Certification and Notice of Termination of Registration
on Form 15 requesting that the Company's reporting obligations under Sections 13
and 15(d) of the Exchange Act be suspended.
Item 3.03 Material Modification to Rights of Security Holders.
The disclosures under the Introductory Note and Items 2.01, 3.01 and 5.03 are
incorporated herein by reference.
At the Effective Time, each holder of Shares outstanding immediately prior to
the Effective Time ceased to have any rights as a stockholder of the Company
(other than the right to receive the Merger Consideration for such stockholder's
Shares), except that those Shares that were owned by the Company or owned by
Parent or Merger Sub were cancelled.
Item 5.01 Changes in Control of Registrant.
The disclosures under the Introductory Note and Items 2.01, 3.01, 5.02 and 5.03
are incorporated herein by reference.
As a result of the Merger, a change in control of the Company occurred, and the
Company became an indirect wholly owned subsidiary of Parent.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
The disclosures under the Introductory Note and Item 2.01 are incorporated
herein by reference.
Pursuant to the Merger Agreement, effective as of, and contingent upon, the
occurrence of the closing of the Merger (the "Closing"), each of Paul R. Auvil,
Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda
C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased
serving as a member of the board of directors of the Company and each committee
thereof.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change of Fiscal
Year.
The disclosures under the Introductory Note and Item 2.01 are incorporated
herein by reference.
Pursuant to the Merger Agreement, effective as of the Effective Time, the
amended and restated certificate of incorporation of the Company and the amended
and restated bylaws of the Company were each amended and restated in their
entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current
Report on Form 8-K, which are incorporated herein by reference.
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
2.1* Agreement and Plan of Merger, dated July 20, 2022, by and among
1Life Healthcare, Inc., Amazon.com, Inc. and Negroni Merger Sub, Inc.
(incorporated by reference to the Current Report on Form 8-K of 1Life
Healthcare, Inc. filed with the SEC on July 22, 2022)
3.1 Amended and Restated Certificate of Incorporation of 1Life
Healthcare, Inc.
3.2 Amended and Restated Bylaws of 1Life Healthcare, Inc.
4.1 First Supplemental Indenture, dated February 22, 2023, by and among
1Life Healthcare, Inc. and U.S. Bank Trust Company, National
Association.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
* Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company
agrees to furnish supplemental copies of any omitted schedules to the SEC upon
its request.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses